Close Menu

Myriad

A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.

The lawsuits were filed after the HHS OIG subpoenaed the firm as part of an investigation into how it billed Medicare and Medicaid for the myRisk test.

The test is approved as a companion diagnostic that can determine which advanced breast cancer patients have BRCA1/2 genetic mutations and will likely respond to Lynparza.

The company has received a subpoena from HHS' OIG as part of an investigation into possible improper billing of its hereditary cancer tests to Medicare and Medicaid.

An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.

The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.

Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.

The firm reported total revenues of $194 million, compared to $196.5 million in Q2 2017, but beat the consensus Wall Street estimate of $188.8 million.

The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.

Expanded Indications

The FDA has expanded the indications for both AstraZeneca's PARP inhibitor Lynparza and Myriad Genetics' BRACAnalysis CDx test, as GenomeWeb reports.

Pages

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.